OUR TEAM
LEADERSHIP
Cameron Durrant, MD, DRCOG, MRCGP, MBA, FLSW
Chairman & CEO
• Serial biotech experience as CEO, CFO, Chair, Exec Chair
• Merck, GSK, Pharmacia, J+J
• Launched 5 blockbusters during career, including antivirals
Dale Chappell, MD, MBA
Chief Scientific Officer
• Founder, Black Horse Capital Advisors
• Decades of biotechnology investment experience
• HHMI Fellow, National Cancer Institute, Rosenberg Lab
• Multiple publications in T-cell therapy, GM-CSF and immunology pathways
Edward P. Jordan, MBA
Chief Commercial Officer
• Over 20 years experience building and leading commercial organizations
• Broad commercial experience spanning many therapeutic areas
• Biotech builder with biologic experience
• Extensive launch experience and builder of new therapeutic markets
• DBV Technologies, AMAG, TEVA, Schering-Plough
Bob Atwill, MBA
Head of Asia-Pacific Region and Business Development
• Over 30 years of executive pharma, biotech, cell therapy and healthcare experience
• Corporate Officer in listed NYSE, NASDAQ, LSE, ASX and in other organisations for over 23-years
• Expertise in COVID-19, GvHD, virology, I/O and cell & gene therapy
• GSK, Sanofi-Synthélabo, Mesoblast and Benitec Biopharma
• APAC based cross-border M&A and capital service principal with Eaton Square